AllRock Bio raises $50 million to drive therapy for pulmonary hypertension into phase 2 trials

Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing

Piramal Pharma Solutions boosts formulation development at Morpeth site with Korsch XM-12

Merck opens €150 million manufacturing facility in Ireland

Merck opens first climate-neutral manufacturing facility in Ireland

Bayer launches biotech innovation platform in China

Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks

Lilly to build $5 billion manufacturing facility in Virginia

This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year

Enveric clears FDA feedback milestone, prepares IND submission for EB-003

IND application for EB-003 expected in early 2026

CIDSCON 2025 emphasized a multi-faceted approach to tackle AMR

The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness

Drug Hunter secures seed investment to scale drug discovery knowledge platform

Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management

Rona submits IND for GalNAc-conjugated siRNA targeting obesity

RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options

Ascletis' ASC30 obesity drug shows 75-day half-life in US Study

Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity